MétaCan
Menu
Back to cohort

Association of changes in biomarkers with treatment with cabozantinib (Cabo) in metastatic castration-resistant prostate cancer (mCRPC): A post-hoc analysis of the 100mg nonrandomized expansion cohort of a randomized discontinuation trial.

2015· article· en· W2589192293 on OpenAlexaff
Raya Leibowitz‐Amit, Melania Pintilie, Alexander Laird, Dana T. Aftab, Raanan Berger, Kim N., Anthony M. Joshua

Bibliographic record

VenueJournal of Clinical Oncology · 2015
Typearticle
Languageen
FieldBiochemistry, Genetics and Molecular Biology
TopicCancer, Lipids, and Metabolism
Canadian institutionsUniversity Health NetworkPrincess Margaret Cancer CentreBC Cancer AgencyUniversity of Toronto
Fundersnot available
KeywordsMedicineClinical endpointInternal medicineCabozantinibProstate cancerOncologyCohortDiscontinuationBiomarkerResponse Evaluation Criteria in Solid TumorsCancerRandomized controlled trialClinical trialPhases of clinical research

Abstract

fetched live from OpenAlex

196 Background: Cabo, an oral inhibitor of receptor tyrosine kinases (RTK) including MET and VEGFR2, showed activity in early clinical studies in mCRPC, and is being investigated in phase 3 trials. Our primary aim was to retrospectively study the potential association between plasma concentrations of known markers of hypoxia, RTK cell signaling, inflammation, bone metabolism, chemo-attraction and epithelial-mesenchymal transition with response to Cabo in patients (pts) who received 100mg daily as part of a phase 2 non-randomized expansion cohort (NCT00940225). Methods: Our cohort of mCRPC pts with available plasma samples comprised of 81 pts with bone lesions assessed for bone scan response (BSR, defined as ≥30% decrease in lesion area compared to baseline). Thirty three pts also had measurable disease and were assessed for RECIST response. Plasma samples were available for all pts at baseline, at 6 weeks and at time of best response. Levels of 27 plasma biomarkers were measured in duplicate using ELISA. Spearman correlation coefficients were calculated for the association between response and biomarker levels at each time point. Results: Sixty six of 81 pts (81%) had a BSR, and 6 of 33 pts (18%) had a partial response by RECIST. No significant associations were found between the levels of any of the biomarkers at baseline or subsequent time points and either BSR or response by RECIST. Over time, the plasma concentrations of soluble VEGFR2 were significantly decreased during treatment with Cabo, consistent with the known effects of VEGFR inhibition on soluble VEGFR2. The plasma concentrations of nine markers (VEGFA, CA9, clusterin, FLT3L, Gas6A, Bone Alkaline phosphatase, and the soluble forms of the RTKs MET, IGF1R and AXL) were significantly increased during treatment with Cabo irrespective of response. Conclusions: These results demonstrate that metabolic alterations occur following treatment with Cabo in pts with mCRPC. Changes in certain biomarkers during treatment with Cabo could suggest potential co-targeting approaches with Cabo or other RTK inhibitors in mCRPC.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.003
metaresearch head score (Gemma)0.002
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Non-randomized trial · Consensus signal: none
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.003
Threshold uncertainty score0.015

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0030.002
Meta-epidemiology (narrow)0.0000.000
Meta-epidemiology (broad)0.0010.001
Bibliometrics0.0000.000
Science and technology studies0.0000.000
Scholarly communication0.0000.000
Open science0.0000.000
Research integrity0.0010.001
Insufficient payload (model declined to judge)0.0020.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.039
GPT teacher head0.381
Teacher spread0.341 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designNon-randomized trial
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations1
Published2015
Admission routes1
Has abstractyes

Explore more

Same venueJournal of Clinical OncologySame topicCancer, Lipids, and MetabolismFrench-language works237,207